Recombinant human erythropoietin (rHuEPO) stimulates erythropoietic bone marrow cells and increases erythrocyte production. This prospective study was designed t o evaluate the effects of rHuEPO on regeneration of erythropoiesis after allogeneic or autologous bone marrow transplantation (BMT). Seventeen centers participated in this randomized, double-blind, placebo-controlled multicenter trial. The randomization was performed centrally for each center and stratified according t o allogeneic or autologous BMT and major ABO-blood group incompatibility. One hundred and six patients received rHuEPO after allogeneic BMT and 109 patients received placebo. After autologous BMT, 57 patients were treated with rHuEPO and 57 with placebo. Patients received either 150 IUlkglday C127 mouse-cell-derived rHuEPO or placebo as continuous intravenous infusion. Therapy stalted after bone marrow infusion and lasted until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels r 9 g/lOO mL or until day 41. After allogeneic BMT, the reticulocyte counts were significantly higher with rHuEPO from day 21 t o day 42 after BMT. The median time (95% confidence intervals) t o erythrocyte transfusion independence was 19 days (range, 16.3 t o 21.6) with rHuEPO and 27 days (range, 22.3 t o >42) with placebo (P < .003). The mean (fSD) numbers of erythrocyte transfusions until day 20 after BMT were 6.6 f 4.8 with rHuEPO and 6.0 f 3.8 with placebo. However, from day 21 t o day 41, the rHuEPO-treated patients received 1.4 f 2.5 (median, 0 ) transfusions and the control group received 2.7 RYTHROPOIETIN (EPO) acts in hematopoiesis primarily on committed erythroid progenitor cells. Together with other hemopoietic growth factors, EPO moderately expands the number of the immature erythroid burstforming units (BFU-E). EPO induces an influx of BFU-E into the compartment of the more mature erythroid colonyforming units (Cm-E) and promotes their further differentiation."' In addition, EPO prevents programmed death of CFU-E, enabling the cells to differentiate into erythrocytes."
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In clinical applications, recombinant human erythropoietin (rHuEP0) stimulates erythropoiesis in anemia caused by deficiency of EPO as in renal insufficiency or renal failure.L'.L2 It is also capable of further activating red blood cell (RBC) production at normal EPO levels. This has been shown in autologous blood donation,I3 patients with myeloma-associated anemia,I4 human immunodeficiency virus (H1V)-infected patients receiving zidovudine therapy,15 and after myelotoxic chemotherapy.16-" Thus the need for erythrocyte transfusions could be reduced by treatment with rHuEPO.
Several historically controlled ~t u d i e s~~-~~ and two small, prospective randomized showed an acceleration of erythropoietic reconstitution after allogeneic bone marrow transplantation (BMT). In these studies, the number of erythrocyte transfusions after BMT was smaller with rHu on thrombopoiesis after BMT,Z',24,25 which was also observed in studies in renal and in multiple myelomaI6 and was found in ~itro.~'*~O In contrast to allogeneic BMT, to date there are no controlled studies with rHuEPO after autologous 4.0 (median, 2) transfusions ( P = .004). In the follow-up period from day 42 up t o day 100, 2.4 f 5.6 transfusions were required with rHuEPO and 4.5 f 9.6 were required with placebo (P = .075). A multivariate analysis (ANOVA) showed that acute graft-versus-host disease (GVHD), major ABOblood group incompatibility, age greater than 35 years, and hemorrhage significantly increased the number of transfusions. However, after day 20, rHuEPO significantly reduced the number of erythrocyte transfusions in these patient groups, as well as reducing incompatibility in the major ABO-blood group. For the whole study period, rHuEPO reduced the transfusion requirements in GVHD 111 and IV from 18.4 2 8.6 t o 8.5 f 6.8 U (P = .05). After autologous BMT, there was no difference in the time to independence from erythrocyte transfusions and in the regeneration of reticulocytes. Marrow purging strongly increased the requirement for transfusions as well as the time t o transfusion independence. rHuEPO had no relevant effect on regeneration of thrombopoiesis after allogeneic or autologous BMT. Overall, no major differences in side effects or complications between rHuEPO-treated and placebo-treated patients occurred. After allogeneic BMT, rHuEPO significantly accelerates the reconstitution of erythropoiesis and reduces the number of erythrocyte transfusions after day 20. The strongest effect occurs in patients with acute GVHD. After autologous BMT, rHuEPO has no clinically relevant effect on regeneration of erythropoiesis. BMT. This double-blind, placebo-controlled randomized trial was conceived to analyze the impact of rHuEPO on 3328 LINK ET AL regeneration of erythropoiesis after allogeneic or autologous BMT.
MATERIALS AND METHODS

Patient Eligibility
Patients receiving an allogeneic bone marrow graft after myeloablative conditioning were eligible for the study if they had one of the following diseases: acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), Hodgkin's disease, non-Hodgkin's lymphoma (NHL), myelodysplastic syndrome, or aplastic anemia. After autologous BMT, patients were eligible if they had AML, acute lymphoblastic leukemia (ALL), CML, Hodgkin's disease, or NHL, with or without bone marrow purging. Patients with erythroleukemia (type M6, French-AmericanBritish [FAB] classification), sickle cell anemia, or @-thalassemia or a Karnofsky score less than 50% were excluded from the trial. Patients receiving another hematopoietic growth factor were not eligible.
Study Design
This was a randomized, stratified, double-blind, placebo-controlled, multicenter trial with 160 patients in each treatment a r m . Sixteen centers in Europe and one in Israel participated in the trial. The study was approved by the Ethics Committee at each institution. It was performed in accordance with the Declaration of Helsinki (Hong Kong Revision 1989). Informed consent was obtained from all patients.
Randomization
Eligible patients at each center were randomized after a telephone call to a central site. Thus variations in treatment protocols between different centers were distributed equally in both groups. Stratification was performed according to allogeneic or autologous BMT and to patients with and without major AB0 blood group incompatibility with the marrow d~n o r .~' The randomization procedure used was a modification of the "minimization method" described by Pocock.'*
Definition of Major AB0 Blood Group incompatibility
Pretreatment anti-A or anti-B isohemagglutinins of the bone marrow recipient capable of reacting with AB0 blood group antigens of the donor were defined as major incompatibility. Other AB0 differences were classified as minor incompatibility.
Preparation of rHuEPO and Placebo
rHuEP0 and Placebo
rHuEPO was expressed by murine cells (C 127 mouse fibroblast cell line) and was produced by Behringwerke AG (Marburg, Germany). The drug had a specific activity of 1.2 X 10' IUlmg of glycoprotein as measured in an in vivo assay according to the World Health Organization standard. Purity of rHuEPO was 99%. as determined by high performance liquid chromatography (HPLC) analysis. The in vivo activity of rHuEPO was shown by clinical trials in endstage renal which was equivalent to data published with recombinant EPO derived from Chinese hamster ovary cells (CHO)."
The vials contained 67.2 pg (8,000 IU) rHuEPO dissolved in 1 mL buffer solution (6.6 mg NaH2P04and 6.4 mg NaCl) and was ready for use.
Vials containing either rHuEPO or placebo were labeled identically. The placebo contained only 1 mL buffer solution 0.1 mom NaCl and 0.05 m o m NaH2P0,, pH 7.8. A set of vials was prepared and numbered for each patient. For continuous infusion, the appropriate daily dose of the study drug was applied in normal saline, 5% glucose, or albumin solution.
Treatment Plan With rHuEPO
rHuEPO was administered at a daily dose of 150 IU/kg body weight as a continuous intravenous (W) 24-hour infusion beginning directly after marrow infusion (day 0). The continuous IV infusion method was chosen in this study, as well as in the preceding phase I1 study," to yield steadily maintained rHuEPO blood concentrations without subcutaneous injections. Furthermore, the daily dosage should provide a maximal stimulatory effect on erythropoiesis. Patients were treated until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels 2 9 gll00 mL, but maximally for 42 days after BMT.
indications for Blood Transfusions
RBC transfusions were required at hemoglobin levels less than 8 gll00 mL and were not allowed at hemoglobin levels greater than 9 gll00 mL.
Platelet transfusions were administered according to the local practice of each center, but were not to be changed during the course of the study.
Evaluation and Criteria for Response
The primary study objective was defined as the time to reach stable, not decreasing hemoglobin levels of at least 9 g/lOO mL for 7 consecutive days without RBC transfusion. The secondary study objectives were the number of erythrocyte transfusions, time to independence from platelet transfusion, and time to discharge from hospital. For safety purposes, all adverse events were documented.
Definition of Independence From Erythrocyte Transfusions
Erythrocyte transfusion independence was defined as the day after the last transfusion, which was followed by 7 consecutive days with a hemoglobin level of at least 9 @l00 mL.
Statistical Analysis
The data were analyzed using standard statistical methods using the PC version of the Statistical Analysis System (SAS) release 6.04 (SAS Institute Inc, Cary, NC). Kaplan-Meier product limit estimates were used to evaluate time-to-event data.34 Ninety-five percent confidence intervals of median time-to-event were derived using the smoothed modified reflected method.3' Two-sided significance testing was based on the Mantel-Haenszel log rank test.36 The time-toevent was defined as the time from the start of blinded treatment until the onset of an event or the last known day without an event. All patients enrolled in the study were considered for analysis. Early death cases and patients not fulfilling the criteria of RBC transfusion independence were treated as censored observations. P values for the difference in laboratory values at a particular time were determined using the two-tailed Wilcoxon-Mann-Whitney test." To explore the role of potential prognostic factors (subgroup analyses), the following regression models were used: analysis of variance (ANOVA) for RBC transfusion amounts, and Cox proportional hazard model for time to erythrocyte transfusion independency. Regression coefficients were tested by means of likelihood ratio tests.'* Regression coefficients and their standard errors in the ANOVA model refer to the additional amount of required RBC transfusions in presence of a specific covariate (eg, patients with hemorrhage versus others).
In the Cox model, regression coefficients were transformed into event ratios by simple exponentiation. Event ratios therefore refer to the ratio of instantaneous probabilities of fulfilling the event of 
Bone Marrow Aspiration and Storage
Bone marrow was harvested under general or regional anesthesia from the posterior iliac crests with suitable needles and was anticoagulated with preservative-free heparin. For allogeneic BMT, the marrow was transfused after volume reduction and, if necessary, plasma and erythrocyte depletion. For autologous BMT the marrow buffy coat was cryopreserved in 10% dimethylsulfoxide and 20% autologous or pooled AB plasma and stored at -196°C.
Treatment Protocols
The high-dose myeloablative chemotherapy or radiotherapy and conditioning protocols for each disease were performed according to the local practice of each center. After 1 or 2 days of rest after ablative treatment, patients received bone marrow as intravenous (IV) infusion. T-cell depletion of the allogeneic marrow or elimination of contaminating malignant cells from the autologous marrow was allowed. These protocols were not changed during the course of the study.
RESULTS
Patient Characteristics
Between August 1990 and September 1992, 329 patients were included in the trial and randomized according to the protocol. After allogeneic BMT, 106 patients received rHuEPO and 109 received placebo. After autologous BMT, 57 patients were treated with rHuEP0 and 57 with placebo.
Demographic data, remission status, patient diagnosis, and the antineoplastic or conditioning therapy received before BMT are summarized in Table 1 . To remove residual malignant cells, in vitro treatment of the autologous bone marrow was performed on 12 patients treated with rHuEPO (9 AML, 1 NHL, and 2 other) with chemotherapy in 9 patients and with monoclonal antibodies (MoAbs) in 3 patients. In 11 patients receiving placebo (9 AML and 2 NHL), the marrow was treated by chemotherapy in 9 patients and with MoAbs in 2 patients.
In allogeneic BMT, the T cells were depleted from the marrow graft in 21 patients treated with rHuEPO and in 21 patients receiving placebo. A major ABO-blood group incompatibility between donor and recipient existed in 22 rHuEPO-treated patients and in 23 patients receiving placebo.
Hematopoietic Recovery
Regeneration of Reticulocytes and Platelets
Allogeneic BMT. The median counts with 25% and 75% quantiles of reticulocytes at weekly intervals are shown in Fig 1A. With rHuEPO, the reticulocytes were significantly higher from day 21 to day 42. The median number of platelets was slightly higher with rHuEPO (52,OOO/pL and 59,50O/pL) compared with placebo treatement (41,OOO/pL and 5 1 ,OOO/pL) at 35 and 42 days, respectively. This difference was statistically not significant.
Autologous BMT. The number of reticulocytes was only slightly higher in rHuEPO-treated patients, but without statistical significance (Fig 1B) . The median number of platelets was similar in both groups. 
Leukocyte Reconstitution
There was no difference in the reconstitution of granulocytes, lymphocytes, and monocytes between patients treated either with rHuEPO or placebo after allogeneic or autologous BMT.
Erythrocyte Transfusions
Allogeneic BMT
Patients treated with rHuEPO needed significantly less time to reach erythrocyte transfusion independence for 7 consecutive days (P = ,003; Fig 2A) . With rHuEPO, the median time to erythrocyte transfusion independence was 19 days, with 95% confidence intervals (CI) of 16.3 to 21.6 days. The placebo patients reached this level of erythroid recovery after a median of 27 days (range, 22.3 to >42 days). The Cox proportional hazard model was used for multivariate analysis of factors with potential influence on time to erythrocyte transfusion independence. Only treatment with rHuEPO significantly reduced the time interval to transfusion independence, with a regression coefficient of. 0.478 ? 0.215, which means an event ratio of 1.61 ( P = .02). Therefore, with rHuEPO therapy, the probability of becoming transfusion independent at any time is I .61 times higher than with placebo. The following variables had no impact: age, diagnosis, early or advanced phase of the disease, bleeding event, cytomegalovirus (CMV) infection, graft-versus-host disease (GVHD), T-cell depletion, A B 0 blood group incompatibility, and HLA match or mismatch.
The analysis of reticulocyte recovery showed a significant effect of rHuEPO only from days 21 to 42. Therefore. the time intervals up to day 20 and from day 21 to day 42 were analyzed separately.
The number of erythrocyte transfusions was similar in both groups until day 20, but significantly smaller from day 2 1 to day 4 1 in rHuEPO patients (Table 2 ). In the follow-up period between day 42 and day 100 after BMT, the rHuEPOtreated patients also needed fewer transfusions than did the control group (Table 2) . Among the single factors with an impact on total transfusion requirements up to day 41, treatment with rHuEPO showed a borderline significant effect for severe GVHD ( P = .05) and absence of bleeding ( P = ,063; Table 2 ). The 8 patients with acute GVHD 111-IV received rHuEPO for a median of 34 days (range, 20 to 42 days) and the 7 respective patients with placebo for a median of 34 days (range, 13 to 42 days).
The ANOVA model was used for multivariate analysis of factors influencing the number of RBC transfusions from day 0 to 41 of the study period. Bleeding events (P = .OS), severe GVHD (P = .03), and major AB0 blood group incompatibility (P = .lo) had an impact at the a = 0.1 level.
The regression coefficients refer to the additional amount of required RBCs in the presence of a specific covariate. The regression coefficients (?SE) for units of transfusions were 1.81 ? 1.04 for hemorrhage, 4.63 L 2.06 for acute GVHD I11 to IV, and 2.13 ? 1.29 for major ABO-incompatibility respectively. The following factors had no relevant influence: treatment with rHuEPO or placebo, age, diagnosis, stage of the disease, CMV infection, T-cell depletion, and HLA match or mismatch.
The ANOVA analysis was also performed for the time period from day 21 to 41. rHuEPO was the only factor with a significant impact ( P = .03) on RBC transfusion requirement. Patients with placebo needed 1.26 t-0.58 more transfusions than the rHuEPO-treated patients (regression coefficient ? SE).
For
Autologous BMT
The median time to erythrocyte transfusion independence was 24 days (95% CI, 16.6 to 30.3 days) after rHuEPO treatment and 27 (13 to 33.5) days ( P = .77) for placebo (Fig 2B) . The Cox proportional hazard analysis showed that bone marrow purging significantly increased the time to independence from erythrocyte transfusions ( P = .009). The regression coefficient ? SE was -1.56 t-0.60, which means an event ratio of 0.21. No influence was shown for rHuEPO treatment, age, diagnosis, disease phase, bleeding event, or CMV infection.
The number of erythrocyte transfusions was not different between both groups during the study period ( Table 2) .
The ANOVA analysis showed that the following factors increased the number of erythrocyte transfusions (P value and regression coefficient t-SE in parentheses): age older than 35 years (P = .06; 1.75 ? 1.03), diagnosis ( P = .04; 4.31 t-2.98 for AML v other), and bone marrow purging ( P = .03; 3.29 t-1.51). rHuEPO treatment, disease phase, bleeding event, or CMV infection had no significant effect on the number of transfusions. Moreover, for those factors with an impact on total transfusion requirements, there was no advantage of rHuEPO treatment (Table 2) .
Platelet Transfusions
The median time (95% CI) to independence from platelet transfusions was 23 days (20.4 to 25.2) after allogeneic BMT with rHuEPO and 21 days (17.6 to 23.4) with placebo. After autologous BMT, the corresponding figures were 24 days (16.5 to 31) for rHuEPO and 22 days (17.1 to 29.7) for placebo. There were no relevant differences in the number of platelet transfusions between the rHuEPO-and placebotreated groups, after either allogeneic or autologous BMT.
Serum Iron and Ferritin
In allogeneic BMT, the median serum iron level was 35.8 pmoVL for rHuEPO patients and 35.5 pmoVL for placebo patients at the day of BMT. The levels declined steadily to values of 22.7 pmoVL at day 42 for rHuEPO and 27.2 pmoY L for placebo ( P < .l). The median serum ferritin value was lower for rHuEPO from day 21 through day 42, as compared with placebo (1,159 to 1,306 pg/L v 1,622 to 1,915 p&; P < . l on days 28 and 42).
After autologous BMT, the median serum iron levels were comparable between both groups, ranging from 25 to 35 pmoVL. The serum ferritin levels were slightly, but not statistically, significantly higher with rHuEPO by days 35 and 42.
Adverse Events
There were no major differences in adverse events and serious complications between the rHuEPO-and placebotreated patients. There were no statistically significant differences. The frequency of all grades of GVHD was 39.6% with rHuEPO and 43.1% with placebo. Veno-occlusive liver disease occurred in 5.7% of rHuEPO-treated patients and 5.5% of patients with placebo after allogeneic BMT; venoocclusive liver disease was not reported after autologous BMT. The incidence of arterial hypertension was 10.4% with rHuEPO and 6.4% with placebo for allogeneic BMT. It was 0% in the rHuEPO group and 5.3% in the placebo group for autologous BMT.
There was no relevant difference between the two groups with respect to the following laboratory serum parameters: total bilirubin, creatinine, alkaline phosphatase, uric acid, total protein, potassium, sodium, and haptoglobin. However, the mean values of lactate dehydrogenase (LDH) were slightly higher in the rHuEPO groups from day 21 to day 42 than in the controls. Alanine aminotransferase and urea were slightly lower in the rHuEPO groups compared with the placebo groups.
DISCUSSION
This prospective, controlled study showed that rHuEPO significantly accelerates the reconstitution of erythropoiesis after allogeneic BMT. The absolute number of reticulocytes was significantly higher with rHuEPO from day 21 until the end of the study at day 42, thus confirming former trials.2'-z3
This delayed effect of rHuEPO after BMT is explained by the target cell population in the marrow. These are the committed erythroid progenitor cells arising over 12 to 23 days after BMT from pluripotent and more immature hematopoietic stem cells." Early after BMT, no erythroid progenitor cells are available on which to exert an influence. Therefore, an earlier effect of rHuEPO after BMT cannot be expected. Thus, if rHuEPO will be applied after BMT, it should be administered from day 14 onward. This might be different if rHuEPO is applied after the use of growth factors acting on the earlier phases of hemopoiesis such as interleukin-3 (IL-3) or stem cell factor. Furthermore, the transplantation of peripheral blood stem cells could provide more rHuEPO-susceptible progenitor cell^.^",^' The expansion of erythropoiesis had no negative effects on the regeneration of thrombopoiesis or granulopoiesis.
With rHuEPO, the time to independence from erythrocyte transfusions was reduced from 27 to 19 days. Previous retrospective studies have reported similar time intervals.2z.23 The multivariate analysis of the time to transfusion independence showed that only therapy with rHuEPO had a significant effect after allogeneic BMT. Other factors had no impact in this statistical test, such as age, diagnosis, disease phase, hemorrhage, CMV infection, acute GVHD, T-cell depletion from the marrow graft, ABO-blood group incompatibility, or HLA mismatch of the marrow donor. However, those factors used in the model showed a goodness of fit of only 0.28. Therefore, other factors not tested here may also be important.
Within the period of 20 days, the number of erythrocyte transfusions did not differ between the two groups. However, after the first 20 days, the rHuEPO-stimulated erythropoiesis led to a significant reduction in erythrocyte transfusions. The follow-up analysis to day 100 after allogeneic BMT showed that the stimulatory effect of rHuEPO continued to reduce the number of RBC transfusions. For the whole study period, rHuEPO reduced the transfusion requirements only in GVHD 111 and IV from 18.4 t-8.6 to 8.5 -C 6.8 U ( P = .05).
The multivariate analysis clearly showed that, besides hemorrhage, acute GVHD and major AB0 blood group incompatibility increased the requirements of erythrocyte transfusion, thus confirming previous report^.^',^'*^^ In the time interval from day 21 to day 41 after BMT, in which rHuEPO significantly stimulated reticulocytosis, therapy with rHuEPO significantly reduced the number of erythrocyte transfusions in these patient subgroups, except for major ABO-blood group incompatibility. rHuEP0 might be clinically useful only in subgroups of patients. The stimulation of erythropoiesis by rHuEP0 in patients without these risk factors is clinically not important.
The endogenous EPO concentrations increase strikingly after beginning the conditioning for BMT, but decrease quickly to low levels."49 It is therefore possible that the exogenous rHuEPO exerts its effect at the time of low endogenous EPO concentrations.
The efficacy of rHuEPO after allogeneic BMT is explained by overcoming the impaired EPO production, which is reduced in response to anemia after allogeneic BMT."5,48.50 Many factors may contribute to this relative EPO deficiency. Cyclosporin A5'.52 and amphotericin B, which are frequently used after allogeneic BMT,53 and cytokines such as tumor necrosis factor (TNF)54.55 can inhibit the EPO production. The malignant disease itself or the preceding chemotherment with rHuEPO compensates for the inadequately low EPO levels. Interestingly, EPO production is more severely suppressed in patients with acute GVHD.45.50 These reports corroborate our results that rHuEP0 was significantly more effective in patients with acute GVHD and most effective in grades 111-IV of acute GVHD. The IL-1-and TNF-induced inhibition of erythropoietic precursors can be abrogated in vitro by ~H u E P O .~' ,~~ These cytokines often are elevated after BMT and especially in GVHD. Therefore, one can assume that in vivo rHuEPO can counteract these suppressive effect on the erythroid progenitor cells.
In autologous BMT, the EPO response to the respective anemia was found to be normal in some report^'^*"^^^^^' and elevated49 or impaired in others.50 However, in the latter study, cyclosporin A had been administered to some patients. This drug inhibits EPO response to anemia even in the absence of nephrot~xicity.~' The number of committed erythroid progenitors (BFU-E) is diminished for 2 to 6 months after autologous BMT.60 Therefore, the CFU-E target cells for rHuEPO arising from BFU-E are in such low numbers that the stimulation by rHuEPO does not become clinically relevant.49 The combination of rHuEPO with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) did not enhance the marrow erythroid cells.61
After autologous BMT, only a minority of patients has inappropriately low endogenous EPO levels in relation to hemoglobin level^.'^^" Hence the EPO reponse to anemia is less blunted after autologous than after allogeneic BMT. Furthermore, the high endogenous EPO levels reported after autologous BMT may be a condition in which the erythropoiesis is least likely to respond to ~H u E P O .~~ Therefore, exogenous rHuEPO has little additional stimulatory effect after autologous BMT. This contrasts with patients with anemia caused by malignant bone marrow infiltration and elevated aPY56*57 may further suppress the EPO response. Thus, treatendogenous EPO levels. In these cases, therapy with rHuEPO may effectively stimulate erythropoiesis.14*L6 However, rHuEPO might have a stimulatory effect on erythropoiesis in patients with poor hematopoietic recovery late after autologous BMT.
In vitro treatment of autologous bone marrow with cytotoxic drugs for removal of residual malignant cells (' 'purging") may reduce the amount of committed hematopoietic progenitors and thus retard erythroid regeneration. Such an effect could be described by prolongation of transfusion dependence and increase of erythrocyte transfusions in case of bone marrow purging. The multivariate analysis of the time to transfusion independence in autologous BMT showed that in patients with AML, bone marrow purging or over 35 years of age required more RBC transfusions. However, rHuEPO was unable to overcome any of these negative effects.
Ferritin and serum iron declined to lower values with rHuEPO in allogeneic BMT from day 28 to day 42, indirectly reflecting the enhanced erythropoietic bone marrow proliferation with rHuEPO. This effect was not observed in autologous BMT.
The median platelet levels were only slightly higher with rHuEPO after allogeneic BMT from day 35 to day 42. The stimulatory effect of rHuEP0 on thrombopoiesis was only weak and clinically irrelevant. The fact that rHuEP0 did not shorten the time to platelet transfusion independence after allogeneic or after autologous BMT is therefore not surprising.
The side effects in both the rHuEPO and the placebo groups were comparable in allogeneic and autologous BMT. Thus, rHuEPO can be administered safely to patients after BMT.
This study did not contain a cost-benefit analysis of the use of rHuEPO. However, one might consider using rHuEPO in patients with high risk of acute GVHD 111-IV and beginning therapy by day 14 after allogeneic BMT. These patients had been treated in the study until day 34, and the amount of RBC transfusions had been reduced from 18.4 to 8.5 per patient. In a recently published placebo-controlled trial with rHuEPO after allogeneic BMT in Sweden, $14 in US currency per 1,000 U rHuEPO were assumed. One unit of CMVnegative RBCs was estimated to cost $145, including the costs for irradiation, filter, and cross-match.z6 The mean weight of our patients was 65 kg, resulting in a daily rHuEPO dosage of approximately 10,000 U. If patients with acute GVHD 111-IV would receive rHuEPO for 20 days, the costs would be $2,800. The cost reduction by saving 10 RBC units would be $1,450. Thus, using this dosage, therapy with rHuEP0 would increase the costs, as they found in the Swedish However, these calculations might be different for each health care system.
We conclude from this study that rHuEPO significantly stimulates erythropoiesis after 14 days after allogeneic BMT, but not after autologous BMT. rHuEPO reduces the number of erythrocyte transfusions 20 days after allogeneic BMT. Then it is most effective in patients with acute GVHD, hemorrhage, or older age or without major AB0 blood group incompatibility.
APPENDIX
The following medical centers and investigators participated in the Erythropoietin after Bone Marrow Transplanta-
